US purchased 28 ReWalk Personal Exoskeletons
6 April, 2017
U.S. Department of Veterans Affairs Purchases 28 Additional ReWalk Exoskeleton Systems to Support National Multi-Center Trial
ReWalk Robotics Ltd.,(Nasdaq: RWLK), announced today that the U.S. Department of Veterans Affairs (VA) purchased 28 ReWalk Personal Exoskeleton Systems for an ongoing national multi-center clinical trial. ReWalk has already shiped 20 systems in Q1 of 2017. Rhe remaining 8 systems from this purchase will be shipped in Q2 2017. The 28 system purchase follows an initial purchase of 20 systems by the VA in 2016, which helped with the initiation of the multi-year, multi-center study.
The clinical trial is the first-ever study conducted in the United States to study the impact of exoskeleton use in a personal setting. The study is enrolling 160 randomized patients, half of whom use ReWalk Robotics’ exoskeleton system and half of whom use standard wheelchairs. Currently, there are six VA centers actively enrolling participants in the study, with four more VA centers set to be included by this summer.
Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. The ReWalk Exoskeleton was designed for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs. The system uses patented motion sensing technology along with battery-powered motorized legs powering knee and hip movement which is controlled by proprietary on-board computers and software. The system allows the user to sit, stand, walk, turn and has the ability to climb and descend stairs. ReWalk is the first exoskeleton to receive FDA clearance.